Daiichi Sankyo, in collaboration with the international NGO, JOICFP, launched the Promotion of cervical cancer prevention through early detection and treatment in Kenya.
In Kenya, breast cancer and cervical cancer are the most common cancers among women, while cervical cancer has become the leading cause of cancer deaths. Additionally, cervical cancer is the most common cancer among women living with HIV (human immunodeficiency virus) and it has been reported that the risk of HIV-positive women developing cervical cancer is four to five times greater than that of women who are HIV-negative. Moreover, the region faces various issues including the lack of proper knowledge and information on cervical cancer and STDs (Sexually Transmitted Diseases) among the local residents, low awareness for prevention and screening, and the insufficient screening and treatment framework offered by the health facilities.
Given the background, this project aims to provide education activities by health volunteers, screening and treatment for cervical cancer, and improved access to the HPV vaccine.
Through these activities, we will contribute to the achievement of Goal 3 “Ensure healthy lives and promote well-being for all at all ages” and Goal 5 “Achieve gender equality and empower all women and girls” of the Sustainable Development Goals (SDGs).
Project overview:
- Region: 3 Counties (Makadara, Kamukunji, and Langata) of Nairobi County, Republic of Kenya
- Activity summary: 1) Provide accurate information on SRHR*1 including information on cervical cancer and STDs to local residents and education activities to encourage behavior modification to promote the prevention and screening of cervical cancer; 2) provide cervical screening and early treatment at health facilities, and 3) strengthen the healthcare network for the screening and treatment of cervical cancer
- Duration: 3 years (July 2022 to June 2025)
- Collaborative partner: JOICFP*2
*1 Sexual and Reproductive Health and Rights, *1*2 Japanese organization for international cooperation to protect the lives and health of women
As a pharmaceutical company with the purpose, to “contribute to the enrichment of quality of life around the world,” the Daiichi Sankyo Group is committed to resolving healthcare access issues in regions with weak healthcare infrastructure.
Project Summary and KPIs